CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
Axitinib +5 moredrug
Likely dose
Bevacizumab 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01490866
NCT01490866Phase 2Completed
CompareCT.gov

A Phase II Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

SCRI Development Innovations, LLC·interventional·Posted Dec 13, 2011·Updated Sep 24, 2019

In Brief

A Phase 2 clinical trial evaluating Axitinib, Bevacizumab, and 3 other interventions for Colorectal Cancer. Completed, enrolled 70 participants across 12 sites.

Detailed Summary

This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 13, 2011
Enrollment StartJan 1, 2012
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 14.6 years ago

Interventions

Axitinibdrug

5-mg tablets PO BID

Bevacizumabdrug

5 mg/kg Days 1 and 15; IV

5-Fluorouracildrug

400 mg/m2 Days 1 and 15; IV

5-Fluorouracildrug

2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous

Leucovorindrug

400 mg/m2 Days 1 and 15; IV

Oxaliplatindrug

85 mg/m2 Days 1 and 15; IV